Assistant or Associate Professor in Cellular Immunotherapy

As a member of an enthusiastic group of dedicated researchers and clinicians, you will strengthen the major research & development program of the LUMC Department of Hematology. The team focuses primarily on developing efficient and specific cellular immunotherapeutic strategies as precision medicine for hematological malignancies and pursues the potential for malignant diseases in general.

You will be responsible for cellular therapeutic strategies that are applied at the LUMC Department of Hematology. This task primarily involves GMP production of ATMPs that are developed by scientists and clinicians within the Department of Hematology itself or in the context of national or European consortia. Currently, we have a leading role in an ongoing EU clinical trial in which patients after allogeneic stem cell transplantation (allo-SCT) are treated with multi-virus specific donor T cells. In addition, a TCR gene therapy in which patients after allo-SCT are treated with donor T cells genetically modified with a hematopoiesis-specific TCR has started patient recruitment in July 2020, and a TCR gene therapy for mutant NPM1 will be implemented in our clinic in the coming year. Furthermore, the Department is the sole institution in The Netherlands holding a hospital exemption to generate and administer virus-specific T cells to treat patients with refractory CMV disease as advanced routine medical care. Finally, you will have the possibility to establish, develop and head your own research group in the field of immunology/hematology, thereby complementing the current research program of the department.


You have a doctorate degree with a proven track record in immunology, hematology or immunotherapy with a strong desire to translate experimental findings into clinical therapies.

You will work in a 36-hour workweek. Appointment is initially for one year, possibly to become tenured. Your salary is based on your education and experience and is based on the collective labor agreement University Medical Centers. 

job type 36-hour workweek
organisation LUMC, Leiden

A detailed description of this position can be found at

If you have any questions or would like more information about this position, please contact Hendrik Veelken, Head of the Department of Hematology, telephone +31(0)71 526 22 67 or Mirjam Heemskerk, associate professor at the Department of Hematology, telephone +31(0)71 526 22 71.

References can be requested as part of the procedure.

How to apply
If you are interested in this position, please complete the application form by September 27th, 2020 at the latest. You can also apply through the website


Interesse? Dan solliciteren via:


organization profile

The LUMC, situated in Leiden, the Netherlands, is an Academic Medical Centre for patient care, research and education, aiming to meet the challenges of tomorrow’s health care. It has a strong focus on research, connecting and combining fundamental research into disease-causing mechanisms with patient-focused studies in areas like oncology, regenerative medicine and population health. The LUMC has research facilities that include capabilities for multiple appliances. The combination with clinical and societal outreach programs allows for ground-breaking research and innovation in basic and applied science.

The Department of Hematology provides a stimulating environment where basic and translational scientists continuously interact with science-minded clinicians. The Department is firmly embedded in the comprehensive cancer center of an internationally leading academic medical center with excellent support facilities. Research at the department has a long-standing focus on cellular interventions after allogenic stem cell transplantations, with the aim to increase the anti-tumor effect of this treatment and to reduce its complications. Based on this experience, the department is officially recognized as Dutch National Center of Expertise for allogeneic stem cell transplantation and cellular immunotherapy. The cellular immunotherapy program takes full advantage of the LUMC interdivisional GMP facility that is fully equipped and licensed for actual production of patient-individual ATMPs, including TCR/CAR gene-modified cells.

print this page
Webdesign © 2008 Strik Design